低中危前列腺癌逐步增加单次剂量的大分割放疗I/II期试验
这项多机构I/II期试验序贯评估三种逐步增加单次剂量(2.94、3.63、4.3 Gy)的大分割放疗方案,共纳入347例低中危前列腺癌患者,结果显示8年生化控制率分别为91.1%、92.7%、88.5%,各级胃肠道和泌尿生殖毒性可接受且相似。
要点
- 三种方案单次剂量2.94、3.63、4.3 Gy,8年生化控制率88.5%–92.7%。
- 7年2级及以上胃肠道和泌尿生殖毒性累积发生率分别为16.3%和22.1%。
- 方案介于中等与大分割之间,为希望缩短疗程者提供选择。
核心结论
- 单次剂量延伸至3.6–4.3 Gy的大分割放疗可获得良好肿瘤学结局,毒性可接受。
研究设计与样本
- 多机构I/II期试验序贯设计三个逐步增加单次剂量的大分割放疗水平,共招募347例低中危前列腺癌患者。
- HPFX I、II、III级分别为64.7 Gy/22次/2.94 Gy、58.08 Gy/16次/3.63 Gy、51.6 Gy/12次/4.3 Gy。
- 主要终点为生化控制和毒性,下一级递增取决于胃肠道毒性是否可接受。
主要发现
- HPFX I、II、III级8年nadir+2生化控制率分别为91.1%±3.0%、92.7%±2.7%、88.5%±4.6%(log rank P=0.903)。
- 7年2级及以上胃肠道和泌尿生殖毒性累积发生率分别为16.3%±2.1%和22.1%±2.4%,三级间相似。
关键数值与推荐
- HPFX I级:64.7 Gy/22次/2.94 Gy;II级:58.08 Gy/16次/3.63 Gy;III级:51.6 Gy/12次/4.3 Gy。
- 低危和中危患者分别占46%和54%,16%患者(主要为中危)接受6个月雄激素剥夺治疗。
临床怎么用
- 对于希望避免常规分割长疗程的低中危前列腺癌患者,可考虑单次3.6–4.3 Gy的大分割方案。
- 治疗决策时应评估胃肠道和泌尿生殖毒性风险,并参考分级递增的毒性数据。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase I/II, multi-institutional trial explored the tolerance and efficacy of stepwise increasing hypofractionation (HPFX) radiation therapy regimens for fraction sizes up to 4.3 Gy in localized prostate cancer. METHODS AND MATERIALS: Three escalating dose-per-fraction schedules were designed to yield similar predicted tumor control while maintaining equivalent predicted late toxicity. HPFX levels I, II, and III were carried out sequentially and delivered schedules of 64.7 Gy/22 fx/2.94 Gy, 58.08 Gy/16 fx/3.63 Gy, and 51.6 Gy/12 fx/4.3 Gy, respectively with next level escalations contingent upon acceptable gastrointestinal (GI) toxicity. The primary endpoints were biochemical control and toxicity. RESULTS: A total of 347 patients were recruited by 5 institutions with 101, 111, and 135 patients treated on HPFX levels I, II, and III with median follow-ups of 100, 85.5, and 61.7 months, respectively (83.2 months combined). The National Comprehensive Cancer Network low- or intermediate-risk group distribution was 46% and 54%, respectively. Sixteen percent of patients, primarily intermediate risk, received 6 months of androgen deprivation therapy. The 8-year nadir + 2 actuarial biochemical control rates for HPFX levels I, II, and III were 91.1% ± 3.0%, 92.7% ± 2.7%, and 88.5% ± 4.6%, respectively (Kaplan-Meier log rank, 0.903). Among clinical covariates, only Gleason score reached near significance in multivariate analysis (P = .054). Twenty-six patients failed biochemically (crude incidence of 7.5%), and there were 5 cause-specific deaths. GI and genitourinary toxicities were acceptable and similar across the 3 HPFX levels. The combined actuarial cumulative incidence of grade 2+ GI and genitourinary toxicities at 7 years were 16.3% ± 2.1% and 22.1% ± 2.4%, respectively. CONCLUSIONS: HPFX employing fraction sizes extending into the 3.6 to 4.3 Gy/fraction range can be delivered with excellent oncologic outcomes. Such schedules, positioned between moderate and ultra-HPFX, may provide additional options for patients wishing to avoid prolonged treatment schedules associated with conventionally fractionated radiation therapy for prostate cancer.
引用
- Ritter MA, Kupelian PA, Petereit DG, et al. A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer. Pract Radiat Oncol. 2020. PMID: 32169590. doi:10.1016/j.prro.2020.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。